Introduction
The eye is a prototypic immune privileged tissue that resists immunogenic inflammation through multiple mechanisms [1, 2] . Inflammatory and immune-mediated diseases in the eye must therefore be viewed against the backdrop of ocular immune privilege. Nevertheless, the eye is subject to inflammatory and para-inflammatory processes. Noninfectious uveitis describes a group of potentially blinding inflammatory ocular conditions of obscure etiology; disease progression in uveitis is thought to be driven at least in part by autoimmune mechanisms. Current concepts in ocular inflammation and the mechanisms that drive it stem largely from studying uveitis in animal models. More recently, it has been recognized that processes that had once been believed to be purely degenerative, such as AMD, diabetic retinopathy, and glaucoma, also involve inflammatory and immune elements [3] . Moreover, studies in patients and in animal models have implicated autoimmune processes in degenerative diseases of the eye [4, 5] , suggesting some anti-inflammatory therapies that are effective for uveitis may be useful for the treatment of AMD.
However, the inflammation observed in uveitis is different from that associated with degenerative conditions in the eye. While uveitis has a major adaptive immune component, AMD and similar degenerative conditions primarily involve innate immune elements [6] [7] [8] . While uveitis is associated with overt inflammation, AMD is slow and insidious (para-inflammation), and acute inflammation is characteristically absent. Here, we critically examine the processes of inflammation and para-inflammation in the eye, comparing and contrasting the associated cellular and molecular mechanisms [9, 10] . Synthesis of the available evidence suggests that (i) autoimmune processes are involved as drivers (if not etiologic triggers) of both the overt inflammatory disease known as uveitis, and the parainflammatory disease typified by AMD; (ii) unlike retinal antigens, the target AMD antigens in the retina are scarce, which limits the adaptive immune response but not innate immune processes; and (iii) the inhibitory ocular microenvironment as part of ocular immune privilege is able to dampen innate immune responses, but is less effective in limiting the function of effector T cells. This in turn enables effector T cells that encounter abundant target antigen in the eye to break down ocular immune privilege and precipitate the development of overt inflammation typical of uveitis.
Ocular immune privilege as a throttle of inflammation in the eye
Immune responses affecting the eye and vision must be viewed against the backdrop of ocular immune privilege. The term was coined in the 1940s by Sir Peter Medawar [11] . It has since been studied intensively, with major conceptual contributions by the late J. Wayne Streilein and his colleagues [1, 2, 12, 13] . The concept that has emerged, and that continues to guide the field today, is that the ocular environment has evolved to limit local immune and inflammatory responses in order to preserve vision. Although specifics are still being debated, it appears clear that immune privilege involves a complex combination of local and systemic mechanisms. These can be thought of as constituting successive layers of defense that are deployed as they are needed. The first line of defense is separation between the immune system and the eye by an efficient blood-retina barrier and little, or no, direct lymphatic drainage of the inside of the globe, which is maintained as long as the eye is intact. If that is breached (as in the case of physical trauma to the eye) and immune cells from the blood enter the eye, the immunoinhibitory ocular microenvironment, composed of diverse soluble and cellbound molecules, steps in to control them. If that is not sufficient and inflammation develops, the eye elicits systemic regulatory mechanisms, experimentally modeled by anterior chamber associated immune deviation (ACAID) and post-recovery eye-dependent tolerance, that can limit the damage. These aspects of immune privilege have been reviewed thoroughly [1, 2, [12] [13] [14] [15] and are summarized in Table 1 .
The concept that we wish to bring forward is that, as part of immune privilege, the inhibitory ocular microenvironment serves as a throttle of inflammation in the eye, exerting significant measure of control over both innate and adaptive immune elements. Past and recent studies have uncovered inhibitory effects of the ocular microenvironment on both innate and adaptive immunity. However, a difficulty has been that many of the studies from which the central concepts of immune privilege arose had been performed in vitro with ocular fluids and cells, extrapolating to an in vivo situation. This was an inevitable consequence of the lack of appropriate tools for an in vivo readout. Nevertheless, where available, we try to point out conclusions based on in vivo data. In keeping with the issues examined in this review, which emphasize the local expression of immunity in the eye, we concentrate on those aspects of immune privilege that act within the ocular microenvironment, rather than systemic aspects.
Immune privilege versus innate immunity
Activation and function of innate immune elements such as natural killer (NK) cells, monocyte-macrophages, neutrophils, and complement are all dampened by the ocular microenvironment [reviewed in [16, 17] . Ocular fluids contain at least two factors that suppress NK cell function: macrophage migration inhibitory factor (MIF) and transforming growth factor (TGF)-b2. These can be shown to turn off NK cells in vitro. It is hypothesized that, together with nonclassical MHC antigens that are expressed by ocular cells, they may also turn off NK cells in vivo, although direct evidence to support this is lacking. Indirect support is provided by the well-documented fact that MHC-unmatched corneal grafts, which by all expectations should have activated NK cells to kill the corneal cells, nevertheless persist and are accepted with high frequency both experimentally and in the clinic [13] . A particularly interesting molecule that has been connected to ocular immune privilege in vivo is FasL, which interacts with both innate and adaptive immune cells. Membrane-bound FasL is expressed in the cornea, iris/ciliary body epithelium and retinal pigment epithelium (RPE). It causes apoptosis of Fas-expressing effector leukocytes and promotes tolerance to antigens within the eye [18] . Ocular fluids also contain a-melanocyte stimulating hormone (MSH) and may contain soluble FasL, a cleavage product of membrane FasL with antagonistic properties [19, 20] . Both these substances inhibit activation of neutrophils (although membrane FasL would activate them [21] ).
A major population of innate inflammatory cells that has been described in most cases of intraocular inflammation is the macrophages [22, 23] . Their activation and function can be dampened by the neuropeptides a-MSH and calcitonin gene-related peptide (CGRP) that are present in ocular fluids. Interleukin (IL)-10 coming from gd T cells appears to be important for systemic manifestation of immune privilege known as ACAID [24, 25] , but it is currently unknown whether a role can be ascribed to IL-10 produced by gd T cells within the ocular milieu. The fact that IL-10 is associated with the regulation of infiltrating ocular macrophages and polarization to the regulatory M2 phenotype, reaffirms the concept of ocular immune regulation of innate responses [22, 23] . The appearance of macrophages with inhibition of neovascularization in the retina in laser-induced damage models, suggest that this is the case [26] . How the role of macrophages is directed in tissue destruction versus regeneration is still unknown, but certainly, the ocular microenvironment has the ability to signal these cells to regulate their function through messengers such as Toll-like receptor (TLR) ligands and macrophage-specific cytokines as well.
Finally, activation of the complement cascade, either by the classical or by the alternative pathway, generates mediators that directly damage target cells by forming a membrane attack complex, and also attract and activate innate immune cells. Data indicate that a low level of complement activation is constantly present in the eye, and may be needed to protect from pathogens. To counterbalance this and control excessive complement activation that would be damaging to the tissue, the ocular fluids and cells express a number of complement regulatory proteins, including the complement factor H (CFH) and the cell bound molecules decay accelerating factor (DAF) and complementrelated receptor gene Y (Crry) (reviewed in [27, 28] ).
Immune privilege versus adaptive immunity
The adaptive immune elements that can express effector function in the eye are CD4 + and CD8 + T cells and antibodies. It is currently unknown whether B cells, which play a systemic role in induction of ACAID, exert any function within the eye besides antibody secretion. CD8 + T cells share many effector characteristics with NK cells and may be controlled in part by similar mechanisms. CD8 + T cells also can act as regulatory cells, whose generation is at least in part driven by interactions dependent on NKT cells in the spleen [29] . The role of CD4 + T cells as effectors and as regulators in the various aspects of immune privilege has similarly been studied extensively in the past. These studies showed that processes that inhibit innate immunity in the eye can often also control adaptive immune cells, and identified new pathways, including membrane-bound FasL, programmed death ligand-1 (PD-L1), cytotoxic T lymphocyte (CTLA-4), and others that act on adaptive responses. While they unquestionably yielded important insights into the ability of the eye to control adaptive immune cells, they were hindered by lack of appropriate tools to study the relevant eye-specific responses in vivo. We have recently re-examined the effects of the ocular microenvironment on naïve and antigen-experienced retina-specific CD4 + T cells using T cells from T cell receptor transgenic (TCR Tg) mice expressing a retina-specific TCR, introduced into the living eye. Data indicate that the living eye efficiently converts naïve retina-specific T cells, into functional forkhead box (Fox)p3 + T regulatory cells (Tregs), or to IL-10-producing T cells (Tr1-like cells?) whose effector function is deficient [30, 31] . This requires recognition of the cognate antigen in the eye (polyclonal T cells are not converted) and is supported by the combined action of TGF-b and retinoic acid; both of which are abundant in the eye. Notably, however, T cells that have already acquired effector function outside of the eye are insensitive to the immunoinhibitory ocular environment. They continue to express effector function and cause fulminant uveitis [31] . Moreover, the already inflamed eye is less able to convert naïve retina-specific T cells to Tregs, indicating that at least this aspect of immune privilege has been (temporarily?) lost as a consequence of inflammation. This may be due in part to the presence of inflammatory mediators in the eye, which can impede Treg induction and function, as well as to depletion from the eye of anti-inflammatory and Treg-inducing factors such as TGF-b and retinoic acid from through the compromised blood-retina barrier [32, 33] . These findings could help to explain how autoimmune uveitis can occur in the face of immune privilege.
Uveitis: inflammation characterized by involvement of adaptive immunity Clinical manifestations
Uveitis manifests as inflammation with a mixed ocular inflammatory infiltrate, containing elements of both the adaptive and the innate immune systems. In posterior uveitis there is typically damage to photoreceptor cells brought about by inflammation, which causes the visual deficit. Uveitis is highly variable in terms of clinical manifestations and disease course. Some types of uveitis are stand-alone and target only the eye (e.g., idiopathic uveitis, sympathetic ophthalmia, and birdshot chorioretinopathy), whereas others are part of a more generalized systemic syndrome (e.g., uveitis accompanying Behçet's disease, Vogt-Koyanagi-Harada's disease, and juvenile idiopathic arthritis) [34] . Associations with T helper (Th)1 and Th17 responses have been reported and could explain some of the observed variability [35] . The autoimmune nature of these diseases is supported by lack of underlying intraocular infection, strong genetic associations with HLA antigens, central involvement of T cells in pathogenesis (evidenced by clinical efficacy of T cell targeting therapies), and immunological responses to unique retinal proteins not found elsewhere in the body. The most frequent responses seen to retinal arrestin (S-Ag) but responses to other antigens are also observed [35] . Evidence that retina-specific T cells detectable in uveitis patients have a role in pathogenesis of their disease comes from clinical data that T cell-targeting therapies, including cyclosporin, rapamycin and IL-2 receptor blockade by daclizumab, have a clinically positive effect on disease. Perhaps the most direct evidence comes from a double-blind placebo controlled trial in which uveitis patients who had lymphocyte responses to S-Ag were given S-Ag orally to induce oral tolerance. The patients fed S-Ag appeared to be able to be weaned off conventional therapy without experiencing a relapse better than the placebo controls [36] .
Recently it has been proposed that some types of uveitis that were considered autoimmune, are in fact autoinflammatory in nature [37] . This stems from the presence of genetic associations with allelic variants of innate immunity receptors [e.g., Behçet's disease and NOD-like receptor family, pyrin domain containing 3 (NLRP3)/cryopyrin mutations [38] and central involvement of IL-1 in pathogenesis. However, this could be an artificial separation that reflects etiology more than pathology, because even in diseases now thought of as autoinflammatory, including Behcet's uveitis, there are demonstrable responses to ocular antigens [39] , whereas other studies report evidence for enhanced Th1 and Th17 responses (although it is not known whether the two are connected) [40, 41] . Therefore, irrespective of the initial trigger, autoimmune responses to retinal antigens released as a result of tissue breakdown may become drivers of disease.
Animal models and mechanisms
To model the complexity of human disease a number of animal models have been developed, which differ in mode of induction, clinical appearance, and immunological mechanisms. Animal models of uveitis have been recently reviewed [35, 42] and a conceptual overview is presented in Table 2 .
The models are based on an adaptive response to a component within the eye; usually a unique retinal protein that functions in vision and is not present in the periphery. The autoimmune models can be either induced, or spontaneous [35, 42, 43] . It should be kept in mind that animal models are invariably amplified to result in a relatively high incidence of disease, otherwise they would not be practical for study. However, this also makes them less than completely physiological. In the case of autoimmune uveitis, the induced models rely on stimulation of the immune system by strong bacterial adjuvants. The spontaneous models rely on a higher than normal autoimmune lymphocyte frequency. In both types of models, innate immune elements participate as ultimate and necessary mediators of tissue damage, but the retina-specific T cells are indispensable to orchestrate and direct the inflammatory response.
Among the induced models, the most studied is the classical model of experimental autoimmune uveitis (EAU), elicited by active immunization with a retinal antigen [e.g., interphotoreceptor retinoid binding protein (IRBP), or retinal soluble antigen (S-Ag), a.k.a. retinal arrestin] in emulsion with complete Freund's adjuvant (CFA) or carried on the surface of dendritic cells (DC) [44, 45] . In place of a real retinal antigen (IRBP or S-Ag; the same antigens shown to elicit memory responses in uveitis patients) there are models that make use of a neo-self antigen such as hen egg lysozyme (HEL) or b galactosidase (b-Gal) introduced into the retina by transgenic technology [46, 47] . T cells play a critical role in disease induction. Antibodies appear to have a diseasemodifying role and exacerbate inflammation that has been elicited by T cells [48] , likely through activation of the complement cascade. This may be because antibodies are excluded from the healthy eye but effector T cells can actively penetrate and break down the blood-retina barrier, whereupon antibodies also can gain access. Among the induced models it is also worthwhile to mention immunogenic uveitis, which is elicited by immunizing the animal to a foreign protein [e.g., bovine serum albumin (BSA) or ovalbumin (OVA)] in CFA, or infusing T cells sensitized to that antigen, and then the same protein is injected into the eye to serve as a target [49, 50] . The model results in a strong intraocular inflammation resembling EAU, and similarly to EAU, it is driven by a vigorous adaptive response. This model will become relevant to our ensuing discussion on autoimmune mechanisms in AMD. In addition to the induced models, several spontaneous uveitis models have been developed. All are based on an excessively high frequency of retina-specific T cells, either due to a retina-specific TCR transgene [42] or to defective thymic elimination of retina-specific T cells [51, 52] . Transgenically introduced neo-self antigens into the retina can also serve as autologous targets when coupled with the relevant transgenic TCR [46, 47] .
Pathogenic immune responses in uveitis
From data in animal models it is clear that T cells specific to retinal antigens play a crucial role in uveitis. It is now well recognized that different T cell effector lineages exist, which normally deal with different types of infections, but each can also become involved in tissue pathology. Th1 and Th17 responses associated with disease have been reported in uveitis patients. In animals immunized for uveitis, both Th1 and Th17 cells specific to the retina are induced. In different models of uveitis, the dominant T cell effector response may be either Th17 or Th1 [44] . Although they recruit different innate effector mechanisms (e.g., Th17 recruits neutrophils whereas Th1 recruits monocytes), both responses are tissue-destructive and independently cause pathology. This is supported by adoptive transfer experiments with in vitro polarized cells, which confirm demonstrate that both T cell effector lineages are fully competent to induce uveitis, even in the absence of the reciprocal effector response in the host [44] .
From numerous studies in human patients and animal models, there emerges the following sequence of events in the pathogenesis of uveitis. Autoreactive T cells specific to retina, which had been activated in the periphery by unknown stimuli, circulate through the body. By chance, they happen to pass through the retinal blood vessels and adhere to the vascular endothelium. Due to their activated state, they produce matrix-degrading enzymes and metalloproteinases and are able to break through the vascular tight junctions comprising the blood-retina barrier and extravasate into the tissue. They are also producing cytokines and chemokines, which activate the (normally quiescent) local antigen-presenting cells (APCs), which then become capable of antigen presentation. The infiltrating T cells must recognize their cognate antigen in situ in order to induce uveitis [35, 50, 53] . It is likely that antigen recognition is necessary to maintain them in a state of activation, whereupon the proinflammatory factors they secrete start a self-amplifying inflammatory cascade: activation of the local microvasculature, recruitment of inflammatory leukocytes and APCs from the circulation, breakdown of the blood-retina barrier, and leakage of retinal antigens into the draining lymph nodes, priming and expansion of additional autoreactive T cells and recruitment of additional inflammatory cells, and enhanced tissue breakdown and antigen release. Thus, a robust antigen-specific effector T cell response, whether Th1 or Th17, recruits and directs the requisite innate effector mechanisms that include innate cellular elements (monocytes, neutrophils, NK cells, and gd cells), as well as adaptive and innate humoral elements (antibodies and complement), that act in concert to cause the physical tissue damage. As discussed above, immune privilege is unable protect against a strong adaptive response. Unlike naïve T cells, primed effector T cells are (i) able to actively penetrate the blood-retina barrier; (ii) not inactivated or converted to Tregs within the eye and continue to express effector function; and (iii) bring about a loss of immune privilege, at least as demonstrated by compromised Treg conversion in the inflamed eye, likely due to loss of molecules that maintain the inhibitory ocular microenvironment through the damaged blood-retina barrier and elaboration of inflammatory mediators [31, 33] .
Inflammation in age-related degenerative disease: major involvement of innate immune elements Clinical manifestations
Life expectancy continues to increase and with it also grows a number of diseases and ailments associated with aging. AMD is a perfect example of this and represents the leading cause of legal blindness in the elderly population of the US, where almost two-thirds of people over 80 years old are afflicted by AMD to some degree [54] . Moreover, 30-50 million individuals suffer from AMD worldwide with frequencies similar to cancer in industrialized countries [55] . The formation of drusen, an accumulation of debris (below the RPE in the macula of aging eyes), is the most common clinical sign identified by ophthalmic physicians. AMD occurs in dry and wet forms: dry AMD relates to damage of the macula caused by atrophy, whereas wet AMD involves blood vessel formation and bleeding. Although the causes of AMD are considered to be multifactorial, oxidative damage (such as the oxidative stress caused by smoking) and neovascularization have been identified as factors associated with progression of the disease [56] [57] [58] . That said, it is important to clarify that causeand-effect relations in AMD have not been clearly established, and while many of the observed hallmarks of the disease, such as drusen, are felt by many to play a role in disease pathogenesis, they could also represent its result.
A major recent advance in the research field of AMD is the association of this degenerative disease with the immune system. Activated complement factor proteins (indicative of innate immunity) have been found in drusen from AMD patients, correlating with genetic polymorphisms within complement factor genes associated with development of AMD, which has led to the notion that inflammation is an important component of this disease [59] [60] [61] [62] [63] and implicated the immune system in the AMD disease process. In addition to the findings that innate/ complement inflammatory responses may play a role in the pathogenesis of AMD, reports from our group and others imply that adaptive immune responses also play a role [3, 4, 8] . The study of animal models of AMD, as discussed below, could provide important clues as to the intrinsic (e.g., the immune system, and genetics) and extrinsic (e.g., oxidative stress) factors that modulate their development and progression, and could potentially lead to prevention or treatment regimens that, by manipulating immune responses, might have significant clinical benefit for this currently intractable and poorly understood disease. In a phase I/II clinical trial in which advanced wet AMD patients were treated with infliximab, rapamycin, and daclizumab in conjunction with the standard of care, anti-vascular endothelial growth factor (VEGF). Both rapamycin and daclizumab (but not infliximab) decreased the number of anti-VEGF injections by approximately half [64] . These encouraging results support the notion that additional anti-inflammatories could be examined for efficacy in wet as well as dry AMD.
Animal models and mechanisms
Unfortunately, the availability of animal models that are representative of AMD or other degenerative diseases of the eye is limited. Only primates and birds have a macula, and although there is an AMD model in monkeys [65] [66] [67] , the disease takes years to develop and studies are difficult and expensive. Research has therefore been hampered by the relative lack of animal models of AMD. Mice, which thanks to the many genetically manipulated strains are the species of choice for basic studies, lack this structure entirely. Therefore, while we can model processes that are believed to be involved in AMD, we cannot model the disease itself. This is in contrast to uveitis, where reasonably good models exist that represent different aspects of human disease. Although there are diverse models of AMD, where the primary lesion is genetic or metabolic, in this review we will primarily focus on animal models of AMD with inflammatory involvement, which can be categorized into genetic and induced models (Table 3) . This is not to say that there is not a secondary involvement of inflammatory mechanisms in models where the primary lesion is not immunological, but they usually have not been studied. Another inherent limitation of AMD models is that, just as models of uveitis are amplified, animal models of AMD are accelerated in order to make them amenable to study in the laboratory. It is arguable to what extent compressing a chronic, lengthy, and smoldering disease process that takes decades in humans, into a short time course able to fit into the lifespan of the mouse, is truly representative of AMD.
The inflammatory gene models of AMD have been developed based on the association between complement factor proteins and genetic polymorphisms found in human AMD [59, 61, 62, 68] . One of them is the, Cfh À/À mouse, in which homozygous mice show uncontrolled C3 activation and accumulation in the retina, and photoreceptor outer segment disorganization [69] . However, contrary to AMD pathological findings, Cfh À/À mice show thinning of Bruch's membrane and reduced drusen deposition instead of membrane thickening and increased drusen-like formations.
Another series of models attempts to address the role of inflammatory (or para-inflammatory?) macrophages in the development of AMD. Macrophages can be found in human AMD lesions adjacent to drusen and may represent a healing and cleanup response gone awry. By altering genes for chemokines and their receptors, mouse models were created that have a deficient macrophage migration and function. Particularly noteworthy are mice deficient in chemokine CC ligand (CCL)2/chemokine CC receptor (CCR)2 responses, which were reported to display an AMD-like phenotype and have been the subject of intense study, which has led to the interpretation that defective macrophage recruitment and/or function due to lack of signaling through this axis leads to degenerative changes in the RPE and retina [22] . Retinal microglial cells share many properties with macrophages and are also thought to play a role in AMD. These cells express the CX3C (fraktalkine) chemokine receptor (CX3CR)1 and homozygosity of the CX3CR1 M280 and V249I alleles is associated with AMD development [70, 71] . Aging Cx3cr À/À mice were reported to display subretinal infiltration of microglia that contain outer segment lipids and these cells show signs of intracellular drusen-like material with age. Combined Ccl2
À/À mice show accelerated AMD-like pathology that progresses to spontaneous CNV in $15% of double mutants. Together, these data could point to a role for both microglia and macrophages in AMD pathogenesis. Unfortunately, data obtained with these models turn out to be difficult to interpret, due to the previously unsuspected contamination of the commonly used C57BL/6N strain with the rd8 mutation of the Crb1 gene, which is expressed in photoreceptor cells and affects their polarity and function. Its presence causes focal degeneration that appears as white spots in the fundus, which upon clinical fundus examination look misleadingly like drusen [72] . Although full expression of the rd8 phenotype was reported to require homozygosity, it is difficult to exclude the possibility that a heterozygous rd8 might interact with or complement expression of other ocular genes, producing a phenotype that would not otherwise be present. Therefore, interpretation of data from mice that display an AMD-like ocular phenotype must be qualified until confirmed to be independent of rd8.
In addition to the spontaneous genetic models discussed above, there are also induced models of processes believed to be involved in AMD. A common approach to model wet or neovascular AMD is the laser-induced model [73] . A green krypton laser is used to create breaks in Bruch's membrane and trigger the development of corneal neovascularization (CNV). Although this model is a response to acute injury rather than a degenerative process, the resulting inflammatory responses are at least in part relevant to similar responses accompanying AMD. For example, a role of macrophage infiltration has been established and findings can be correlated to wet AMD [23, 26] . Other models of induced disease include light-induced and smoking-induced AMD model [74, 75] . Interestingly, of these, in the smoking model, affected mice show pathological traits reminiscent of dry AMD, including RPE loss, thickening of Bruch's membrane, and accumulation of subretinal debris after 4-5 months. This has been associated with oxidative stress and triggering of immune processes in the eye [76] .
To directly explore the relationship between immunity and AMD, we developed an induced immune-mediated model of AMD. This approach was based on studies of patients with AMD in whom carboxyethylpyrrole (CEP)-adducts were found in greater numbers in patient drusen and higher titers of anti-CEP autoantibodies in patient plasma were detected when compared to age-matched control subjects [4, 5] . CEP is an oxidative byproduct from the fatty acid docosahexaenoic acid (DHA). DHA is mostly found in the retina; a tissue that is highly susceptible to oxidative damage and light exposure, and the model examines the effect of immunization of wild type (WT) mice with CEP-modified self-antigens compared to immunization controls. Over time, CEP-immunized mice develop an AMD-like pathology manifesting as RPE cell hypertrophy and vacuolization, inflammatory cell recruitment in the subretinal space and outer segments, as well as RPE cell lysis. This model supports the interpretation that oxidative processes and tissue damage, irrespective of the way in which they are triggered, result in formation of new molecules that are antigenic to the immune system. These then serve as an antigenic target for adaptive immune processes that step in to participate in retinal tissue damage. In addition to supporting a role for adaptive immune mechanisms in the pathology of AMD, this model may serve as an effective way to decrease the threshold of inflammatory processes that put retinal tissue at risk of developing RPE cell dysfunction and retinal degeneration at early time points post-immunization, providing an accelerated model to study an age-related disease.
Pathogenic immune responses in AMD
In inflammatory processes such as uveitis, presentation of autoantigen in the context of infection providing a bacteria adjuvant effect, results in generation of an immune response that triggers the recruitment of inflammatory cells and mediators to the affected tissue. Interestingly, in AMD tissue stress and malfunction also induce an adaptive immune response, but the tempo and magnitude of inflammation are significantly smaller and the participating immune elements are distinct. This response, known as para-inflammation has been coined by Medzhitov and described to mainly rely 'on tissue-resident macrophages and is intermediate between the basal homeostatic state and a classic inflammatory response' [77] . In other words, para-inflammation is implicated in chronic inflammatory conditions associated with modern human diseases and represents a tissue response to oxidative stress stuck in limbo between tissue repair and inflammation, in order to restore functionality and stability. In contrast to uveitis, immunity to retinal antigens associated with aging produces a response that is more reminiscent of parainflammation than inflammation.
The immunology of AMD could apply to para-inflammation in general, including the role of macrophages and T cells. Macrophages have been the subject of close inspection in the context of AMD, but our present knowledge regarding the role of T cells is surprisingly limited; mainly provided by studies of Nussenblatt and colleagues [78] . They have shown that complement components can induce IL-22 and IL-17 expression by human CD4 + T cells and that elevated levels of these cytokines are present in AMD patients. However, the identity of antigen-specific T cells that might mediate AMD pathology and how they interact with other immune cells (e.g., macrophages and B cells) remains to be elucidated.
As alluded to above, a potential link between innate and adaptive immune para-inflammatory responses in disease is oxidative stress, a known contributing factor in the development of pathological inflammatory conditions, including atherosclerosis and AMD [7] . Much of the evidence for adaptive immunity in AMD comes from the presence of antiretinal autoantibodies in AMD patients [79, 80] , which is recapitulated in our CEP mouse model mentioned above [4] . It is not clear whether the antibodies found in in human AMD patients have a primary role in AMD etiology, or if they arise in response to tissue breakdown products. Nevertheless, we would suggest that once present even as a secondary phenomenon, they can become drivers of disease. A role for antibodies in AMD progression is supported by observations in autoimmune retinopathy (AIR); a collection of disorders that includes cancer-associated retinopathy, melanoma-associated retinopathy, and nonparaneoplastic autoimmune retinopathy. Anti-a-enolase and anti-recoverin autoantibodies from CAR patients induced apoptotic cell death in retinal cells, and presence of particular antibody specificities is so strongly associated with disease that it serves as a diagnostic criterion for AIR [81, 82] . Although extensive studies have yet to be conducted for AMD, particular antibody specificities associated with AMD are beginning to emerge [80, 83] . Interestingly, despite its recognized autoimmune pathogenesis, AIR takes on the form of degeneration rather than overt inflammation.
Relevant to T cell responses, lipid peroxidation has been shown to produce oxidation-specific epitopes that can function as new antigens for immune recognition. In the context of AMD, CEP-modified proteins are known to be immunogenic and associated with development of disease. In addition, CEP acts directly and indirectly to influence macrophage polarization. On the one hand, it can directly activate macrophages, leading to M1 gene expression [8] . On the other hand, proinflammatory cytokine (interferon-g and IL-17A) production by CEP-specific T cells contributes to the polarization of macrophages toward the M1 phenotype, providing a functional link between adaptive and innate immunity in the onset of disease. Malondialdehyde (MDA) is another lipid peroxidation product that serves as a marker of oxidative stress. MDA is formed upon peroxidation of polyunsaturated fatty acids present in phospholipids of low-density lipoprotein (LDL), and has been associated with a number of oxidative-stress-related diseases, including atherosclerosis and AMD [84] . Interestingly, it has been shown to bind to and be inhibited by CFH, which has been associated with regulating susceptibility to AMD [59, 61, 62, 68, 69] . These lipid modifications of self-proteins induced by oxidative stress in the retina, such as albumin in the case of AMD, function as haptens that can induce a T cell autoimmune response. Unlike retinal antigens involved in uveitis, these seem to elicit a para-inflammatory rather than a full-blown inflammatory response.
We hypothesize that the amount of adducted retinal antigen or other AMD-related antigen available as target in the eye could at least in part account for the difference between the development of para-inflammation versus inflammation. In the case of CEP, a likely determining factors in macrophage polarization and AMD could be differences in drusen CEP patterns, driving local foci of increased inflammation, and high versus low retinal CEP content. It is also interesting that increased levels of CEP have been found in cone photoreceptor cells of postmortem eyes from healthy donors [8] . Since the macula (the region affected in AMD) contains the highest concentration of cone cells in the eye, it is tempting to speculate that this could be a harbinger of the propensity to develop AMD.
While age-related modifications in proteins within the retina are well documented, there is a paucity of studies on effects of aging on the local parameters of immune privilege, that is, intactness of the blood-retina barrier and the inhibitory ocular microenvironment. One study reports that FasL in the mouse retina actually becomes upregulated with age [85] . Nevertheless, the role of FasL in immune privilege remains somewhat controversial due to findings that FasL can be both pro-and anti-inflammatory. Interestingly, the same study reports that aging increases circulating levels of soluble FasL (a finding also reported in humans), which enhanced laser-induced CNV by attracting M2 proangiogenic macrophages into the laser lesions. However, this does not bear on immune privilege, because (i) the level of circulating sFasL is likely the result of systemic inflammatory process; (ii) the lasering process itself caused downregulation of retinal FasL, which inhibits neovascularization in the eye by causing death of (Fas-expressing) new vessels [86] ; and (iii) although CNV is used to model angiogenesis that occurs in wet AMD, it is a healing response to acute injury, not a degenerative process per se.
Concluding remarks
Whereas in uveitis we see an overt inflammation, AMD is characterized by covert inflammation [9] . Why are these different, especially if they both have autoimmune underpinnings? Uveitis represents an aberrant response to self, brought about by a combination of two failures in selftolerance. On the one hand, ineffective central tolerance, possibly due to low expression of retinal antigens in the thymus in some individuals [87] , permits retina specific T cells to escape elimination in the thymus. This is combined with inadequate peripheral tolerance, ironically as a result of immune privilege, which involves sequestration of retinal antigens in the eye and impedes peripheral tolerance [12] . On the other hand, in AMD the response to neoantigens such as CEP, generated in adulthood through interaction with the environment, could be viewed as a legitimate immune response to non-self [7] . However, this by itself cannot explain why the effector mechanisms engaged in both situations should be different.
A necessary step in development of autoimmune inflammation driven by the adaptive response is recognition of the autoantigen in the retina. A possible reason for the covert inflammation in AMD could be paucity of the target antigen in the retinal tissue. The amount of oxidativestress-induced neoantigens in the retina as a function of age and environmental conditions has not been measured, but since it is a gradually accumulating product of metabolic processes, its amount (at least in younger animals) is probably small. It is conceivable that following immunization, the activated CEP-specific T cells simply do not find sufficient target antigen to become efficiently reactivated when they enter the eye. IRBP in the cat retina is reported to be present at >600 mg/g protein [88] and in bovine retina $2 mg/g retinal tissue [89] (note that the method of quantitation differs). BG2 mice, expressing transgenic b-Gal in the retina under control of the arrestin promoter as a neo-self antigen, have 10-fold less b-Gal in the retina than IRBP (D. Gregerson, personal communication). When crossed with b-Gal TCR Tg mice, introducing a high frequency of TCRs for the target antigen, they do not develop spontaneous uveitis, in contrast to IRBP-TCR Tg R161H mice. This could be a consequence of reduced antigen in the retina [42, 46] . However, uveitis can still be induced in these mice by immunization, so this level of expression is able to support an adaptive inflammatory response. The amount of CEP in the retina of a young mouse immunized with CEP-adducted protein is unknown, but is likely to be much less than that. We hypothesize that the slow accumulation of CEP in the retina as the mice age and sustain oxidative changes may provide a gradually increasing, but still low-abundance target, explaining the late onset and low grade of inflammatory activity in the CEP immunization model.
We further propose that intraocular levels of the molecular guardians of immune privilege (CFH, inhibitory neuropeptides, TGF-b, and retinoic acid), which are rapidly lost in uveitis [33] , are largely preserved in CEP-AMD, and in AMD in general, allowing the inhibitory ocular environment to exert a significant measure of control on the (mostly innate) inflammatory activity, and dampening what otherwise might become a more overt inflammation, into para-inflammation. If correct, injection of CEPadducted protein into the eye of a CEP-immunized mouse should precipitate a more overt inflammation, similarly to the model of immunogenic uveitis, where injection of BSA into eyes of BSA-primed mice provides an abundant target for the adaptive response and precipitates inflammation.
The hypothesis proposed herein, aimed at outlining the immune mechanism that underlie the distinct forms of inflammation observed in inflammatory diseases of the eye, has testable predictions. We hope that interested investigators will put these premises to the test, and in this way shed light on the complex processes through which the immune system is involved in ocular homeostasis and disease.
